Early lung disease in cystic fibrosis

Area of Science:

• Pulmonology
• Pediatric Medicine
• Genetics

Background:

• Cystic fibrosis (CF) lung disease involves inflammation and infections, leading to progressive pulmonary function decline and respiratory failure.
• While early management improves initial lung function, the rate of decline in older patients remains a challenge, highlighting the critical importance of early disease stages.
• Current CF treatments are shifting from symptomatic relief to disease-modifying interventions targeting underlying mechanisms.

Purpose of the Study:

• To summarize current knowledge on characterizing and quantifying early lung disease in cystic fibrosis.
• To discuss treatment strategies, including emerging therapies, for managing early-stage cystic fibrosis lung disease.
• To explore the potential of the infant and preschool age range (2-5 years) as a critical period for intervention.

Main Methods:

• Review of current literature on early cystic fibrosis lung disease.
• Analysis of methods for characterizing and quantifying early lung disease.
• Discussion of existing and novel therapeutic strategies for early intervention.

Main Results:

• Early management significantly improves initial pulmonary function in cystic fibrosis patients.
• The annual decline in pulmonary function in older patients has not changed, underscoring the need for effective early interventions.
• The infant and preschool period presents a unique opportunity to intervene and potentially prevent or postpone the onset of cystic fibrosis lung disease.

Conclusions:

• The infant and preschool years (ages 2-5) are a critical window for intervening in cystic fibrosis lung disease.
• Preventive or causal therapeutic strategies are essential for altering the natural course of cystic fibrosis lung disease.
• Further research into novel treatments and early detection methods is vital for improving long-term outcomes in cystic fibrosis.